Brodalumab in the Treatment of Immune-Related Adverse Events

Clinical trial NCT06673329 · RECRUITING

Trial details

NCT number: NCT06673329
Sponsor: Brian Henick, MD
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Esophageal Cancer Kidney Cancer Lung Cancer Thyroid Cancer Gynecologic Cancer Pancreatic Cancer Stomach Cancer Brain Tumor Colon Cancer Rectal Cancer Head and Neck Cancer

Start date: 2025-03-11
Primary completion: 2027-05-01
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.